Safety and pharmacokinetics of ONC201 (dordaviprone) administered two consecutive days per week in pediatric patients with H3 K27M-mutant glioma.
Odia Y, Koschmann C, Vitanza NA, de Blank P, Aguilera D, Allen J, Daghistani D, Hall M, Khatib Z, Kline C, MacDonald T, Mueller S, Faison SL, Allen JE, Naderer OJ, Ramage SC, Tarapore RS, McGovern SL, Khatua S, Zaky W, Gardner SL.
Odia Y, et al. Among authors: tarapore rs.
Neuro Oncol. 2024 May 3;26(Supplement_2):S155-S164. doi: 10.1093/neuonc/noae001.
Neuro Oncol. 2024.
PMID: 38400780
Free PMC article.
Clinical Trial.